OHB-607 Emerging Drug Insight

"OHB-607 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about OHB-607 for Bronchopulmonary Dysplasia (BPD) in the seven major markets. A detailed picture of the OHB-607 for BPD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the OHB-607 for BPD.

 

The report provides insights into the mechanism of action, dosage and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the OHB-607 market forecast analysis for BPD in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies in bronchopulmonary dysplasia.

Drug Summary

Oak Hill’s lead therapeutic candidate, OHB-607 (formerly TAK-607), is a proprietary, recombinant version of insulin-like growth factor 1 (IGF-1), the natural version of which is a key driver of fetal growth and development in-utero, and its binding protein, IGFBP-3.

 

IGF-1 plays an important role in the development of the fetus, and the mother supplies it until about 30 weeks of gestation, after which the fetus begins producing the growth factor on its own. Levels of IGF-1 dramatically decrease in infants born extremely prematurely (before 28 weeks of gestation), thereby increasing the risk for complications related to the lungs, brain, eyes, and other organs. OHB-607, as a human IGF-1 replacement, is designed to help promote the continued development and maturation of vital organs and the vasculature that supports them.

 

OHB-607 has been evaluated in both preclinical and clinical studies to treat BPD. A Phase II clinical trial showed a statistically significant shift toward milder BPD and a positive trend in reducing intraventricular hemorrhage (pre-specified secondary endpoints), with no significant safety signal observed.

 

It is currently being investigated in Phase IIb trial in multiple indications, including BPD, chronic lung disease (CLD) of prematurity, intraventricular hemorrhage (IVH), and retinopathy of prematurity (ROP) in extremely premature infants as an intravenous infusion in extremely premature infants.  

Scope of the Report

The report provides insights into the following:

• A comprehensive product overview including the OHB-607 description, mechanism of action, dosage and administration, and research and development activities in BPD.
• Elaborated details on OHB-607 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OHB-607 research and development activities in BPD across the United States, Europe and Japan.
• The report contains forecasted sales of OHB-607 for BPD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for BPD.
• The report also features the SWOT analysis with analyst views for OHB-607 in BPD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OHB-607 Analytical Perspective by DelveInsight

In-depth OHB-607 market assessment

This report provides a detailed market assessment of OHB-607 for BPD in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data for OHB-607.

 

OHB-607 clinical assessment

The report provides the clinical trial information of OHB-607 for BPD covering trial interventions, trial conditions, trial status, and start and completion dates.

Report Highlights 

• In the coming years, the market scenario for BPD is set to change due to the extensive research and incremental healthcare spending worldwide; this would expand market size to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OHB-607 dominance.
• Other emerging products for BPD are expected to give tough market competition to OHB-607, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provide the current development scenario of OHB-607 in BPD.
• Our in-depth analysis of the forecasted sales data of OHB-607 will support the clients in decision-making regarding their therapeutic portfolio by identifying the overall scenario of the OHB-607 in BPD.

Key Questions

• What is the product type, route of administration and mechanism of action of OHB-607?
• What is the clinical trial status of the study related to OHB-607 in BPD, and the study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OHB-607 development?
• What are the key designations that have been granted to OHB-607 for BPD?
• What is the forecasted market scenario of OHB-607 for BPD?
• What are the forecasted sales of OHB-607 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What other emerging products are available, and how are these giving competition to OHB-607 for BPD?
• Which are the late-stage emerging therapies under development for the treatment of BPD?